Brief: Sino Biopharmaceutical's Culmerciclib Capsule Receives NMPA Approval For First-Line Hr+/Her2- Advanced Breast Cancer In China
06/05/2026 12:04
May 6 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: CULMERCICLIB CAPSULE RECEIVES NMPA APPROVAL FOR FIRST-LINE HR+/HER2- ADVANCED BREAST CANCER IN CHINA CULMERCICLIB RECEIVES SECOND INDICATION APPROVAL IN CHINA CULMERCICLIB PLUS FULVESTRANT SHOWS 44% RISK REDUCTION IN PHASE III TRIAL Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit